Sarah Speight

Articles by Sarah Speight

Pharma

Humira: lessons from 20 years of patents, pricing and profits

As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.   21 March 2023

Biotech

UK industry welcomes Budget boosts for life sciences

New R&D tax incentive announced for SMEs in UK Budget | Funding for medicines regulator aims to open up drug approvals | ‘Hidden benefits’ in Budget for industry | Reaction from Bioindustry Association, Potter Clarkson, Mischon de Reya, Marks & Clerk, Taylor Wessing.   16 March 2023

Biotech

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.   9 March 2023

Pharma

WIPO: Pharma patents dwindle against record total growth

Health-related patents fell during 2022 against a backdrop of record global patents filed | Biotechnology was fastest growing field among Patent Cooperation Treaty applications | COVID-19 pandemic caused large falls in goods classes such as pharmaceuticals.   2 March 2023

article

Apple suffers another bruising in smartwatch tech clash

Tech giant faces second setback in a month in dispute with Masimo | Patent Trial and Appeals Board denies its request for IPR.   31 January 2023

Americas

Could Apple face an ITC import ban of its watches?

With wearable health monitoring technology booming, Apple is facing several challenges to its smartwatch patents from medtech firms, and ITC investigations threatening import bans in the US. Sarah Speight reports.   17 January 2023

article

UKIPO appoints permanent chief executive

Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.   13 December 2022

article

Analysis: Ventria on ITC win barring rHSA products

Counsel for Ventria sat down with Sarah Speight to explore their landmark win at the International Trade Commission, which led to a US ban for a Chinese company   3 November 2022

article

CMS adds two senior hires to its IP team in the UK

The firm has strengthened its Sheffield office with a senior patent attorney who joins from GlaxoSmithKline.   25 October 2022

Pharma

UPDATED: ITC blocks Chinese imports of rice-derived rHSA products after ALJ review

Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.   20 October 2022

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.